Despite the pathophysiological and clinical differences between AD and PD, the basis for the use of GLP-1RAs in the treatment of these diseases is precisely the general mechanisms of their pathogenesis and risk factors, including T2DM and insulin resistance, abnormal accumulation of toxic proteins, increased inflammation, decreased synaptic function, loss of neurons, increased activation of astrocytes, leading to cognitive dysfunction [43]
EClinicalMedicine 40:101125
This aligns with the body-first PD subtype theory, suggesting that peripheral initiation may precede CNS involvement (Goedert et al., 2017
Do GLP-1 weight loss injections cause low blood sugar
But its ads tell a much different story, promoting misleading starting at prices of $129 and GLP-1s starting at $30/mo. The $30 figure is for a three-month supply of metformin, which is not a GLP-1, and the $129 refers to a limited time microdose option